AzTrials
AzTrials

OsteoporosisTWINBONENCT07508553

Comparison of Bone Mineral Density in the Third Trimester Between Women in Singleton and Twin Pregnancies Using Questionnaires and REMS Densitometric Examination

A study testing bone densitometric examination using REMS technology and questionnaires in people with Osteoporosis and Pregnancy, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This clinical study aims to monitor and evaluate bone mineral density and fracture risk in women with singleton and twin pregnancies through the combined use of: two specific questionnaires developed by the Fragility Fracture Observatory (OFF), and a bone densitometric examination using REMS technology, performed… Read more about this study

Who is it for?
Ages 30 to 45 years, women onlyHealthy volunteers can take part
Conditions the study is for
Osteoporosis, Pregnancy, Twin Pregnancy
What is being tested?
bone densitometric examination using REMS technology and questionnaires
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteItaly
Study dates
23 Dec 2025to 23 Dec 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 45 years
  • Women only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Signed informed consent
  • Willingness to participate in the study and ability to complete the study questionnaires
  • Women between 35 and 41 weeks of gestational age at the time of study inclusion
  • Singleton or twin pregnancy (dichorionic or monochorionic)
  • Age between 30 and 45 years at the time of study recruitment
  • No history of recent or previous bone fractures or traumatic fractures, and no motor disabilities (in the mother).
Show all 10Show fewer
  • Absence of a diagnosis of osteopenia or osteoporosis according to the criteria of the Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS).
  • No intake of vitamin D or other medications during pregnancy.
  • Absence of current or previous conditions that could potentially interfere with bone metabolism (e.g., thyroid, kidney, or liver disease).
  • Women of normal weight or with class I obesity (BMI between 18.5 and 34).

Who cannot join

  • Patients will not be included in the study if at least one of the following exclusion criteria is met:
  • Failure to sign the informed consent form
  • Poor compliance and/or inability to complete the study questionnaires
  • Women with previous or newly diagnosed comorbidities during pregnancy
  • Age <30 and >45 years
  • Previous diagnosis of osteopenia or osteoporosis according to the criteria of the Italian Society for Osteoporosis, Mineral Metabolism and Bone Diseases (SIOMMMS)
  • BMI <18.5 or >34

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Italy1 site, 1 recruiting
  • Fondazione Policlinico Universitario A. Gemelli IRCCS

    Roma, RM, 00168

    Tullio ghi, 0630155989, tullio.ghi@policlinicogemelli.it

    chiara Del prete, 3913187130, chiara.delprete02@icatt.it

    Recruiting

Other trials in Italy

About this study

Official title: Pregnancy-associated Reduction in Bone Mineral Density: a Comparative Study Using REMS Technology Between Singleton and Twin Pregnancies in the Third Trimester

This clinical study aims to monitor and evaluate bone mineral density and fracture risk in women with singleton and twin pregnancies through the combined use of:

  • two specific questionnaires developed by the Fragility Fracture Observatory (OFF), and
  • a bone densitometric examination using REMS technology, performed between the 35th and 41st week of gestation.
Read more

Primary objective:

  • To identify, in the third trimester of pregnancy (between the 35th and 41st gestational week), any differences in bone mineral density (BMD) between women with singleton pregnancies and women with dichorionic and monochorionic twin pregnancies.

Secondary objectives:

  • Evaluate the relationship between bone mineral density (BMD) values and maternal clinical and historical parameters, such as age, body mass index (BMI), and obstetric and medical history.
  • Evaluate the association between BMD values and scores obtained from validated questionnaires administered to investigate fracture risk and bone health-related quality of life in women with singleton and twin pregnancies.
Read the detailed description

Upon enrollment, gestational history, maternal clinical conditions, drug therapy, demographic and anthropometric parameters will be recorded, and specific questionnaires developed by the Fragility Fracture Observatory (OFF) will be administered. These questionnaires aim to assess all risk factors that could lead patients to have a fracture during pregnancy and to evaluate both dietary habits (specifying the type of food with high, medium and low calcium content with relative portions and frequencies) and adherence to the Mediterranean diet (determining, based on the total score, whether the dietary calcium intake is sufficient to support the physiological adaptation of the pregnant woman, who must provide adequate amounts of calcium for the development of the fetal skeleton and the correct growth of the newborn during breastfeeding).

The first questionnaire is divided into two sections: one specifically for "calcium intake" and the other dedicated to assessing the woman's eating habits (Predimed Questionnaire) during pregnancy, which measures portion sizes and the frequency of nutrient intake through food and beverages.

The second questionnaire, AFEF (Fracture Risk Algorithm for Women of Childbearing Age), specifically assesses fracture risk during pregnancy. It collects anthropometric information (weight and height), medical history and personal and family medical history, lifestyle (number of cigarettes smoked daily), and any therapies undertaken before and during pregnancy.

An assessment of bone health using ultrasound densitometry using REMS technology, integrated into the EchoStation device (Echolight Spa, Lecce, Italy), is performed during the third trimester checkup.

The importance of using REMS ultrasound lies in its complete absence of ionizing radiation, ease of use, and rapid scanning. Thanks to an innovative parameter called Fragility Score (FS), intrinsically correlated with bone quality and independent of BMD, REMS allows for the assessment of bone fragility and its resulting fracture risk, representing a useful diagnostic tool also in predicting the risk of fragility fractures. All of this makes this method absolutely compatible and optimal for routine monitoring of bone health and fracture risk in women during pregnancy.

The objectives of the REMS ultrasound technology are:

  1. To obtain a quantitative and qualitative assessment of bone status at the proximal femur level in all patients enrolled in the study, stratifying them into two groups based on the BMD values obtained (normal and reduced).
  2. To evaluate, using the REMS-based Fragility Score (FS), the risk factors associated with changes in bone fragility, and to identify the cut-off for the FS measured at the femoral neck specifically for pregnant women.

The EchoStation device (manufactured by Echolight Spa) consists of a medical-grade cart, which houses a panel PC, a medical-grade keyboard and mouse, a main unit, and a convex probe operating at a nominal frequency of 3.5 MHz. The EchoStudio software, integrated into the EchoStation device, dedicated to assessing bone health, allows for the automatic calculation of the same diagnostic parameters provided by a DEXA scan (Bone Mineral Density (BMD), T-score, and Z-score) from unfiltered ultrasound radiofrequency signals acquired during an ultrasound scan of a reference anatomical specimen (femoral neck). The ultrasound signals of the bone region in question are automatically processed and compared with reference spectral models previously derived from healthy and osteoporotic patients in order to assess the subject's bone mineral density; and with previously derived reference spectral models from patients with and without fractures to assess bone fragility and related fracture risk using the innovative FS parameter.

This approach, unlike conventional ultrasound, maximizes the information gathered from the acquired signals, while the reconstructed B-mode ultrasound images serve as a guide for the correct identification of the bone being examined. The simultaneous acquisition of multiple ultrasound signals for each frame is integrated with the ultrasound imaging, which also serves as a guide for identifying the region of interest (ROI) within the bone being examined, providing a solid and reliable statistical basis for subsequent analyses.

Women between the 35th and 41st week of gestation (inclusive) will undergo ultrasound examination of the proximal femur using an EchoStation ultrasound system (Echolight Spa, Lecce, Italy) with a convex probe operating at a nominal frequency of 3.5 MHz. Trained operators will follow a standard procedure. Specifically, a 40-second software-guided ultrasound scan will be performed with the ultrasound probe positioned at the head-neck axis of the femur. The probe will be positioned parallel to the long axis of the femur, and the transducer focus and scan depth will be appropriately set to place the femoral neck interface in the focal zone of the beam and in the central portion of the image. The software will then automatically analyze the unfiltered ultrasound signals, identifying the bone interface and ROI; the resulting signals will be processed and, after this automatic process, the diagnostic report will be produced.

Being tested
bone densitometric examination using REMS technology, questionnaires
Keywords
pregnancy, twin pregnancy, bone mineral density, ultrasound densitometry
Medical subject headings
Osteoporosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • bone densitometric examination using REMS technologyDevice

    An assessment of bone health using ultrasound densitometry using REMS technology, integrated into the EchoStation device (Echolight Spa, Lecce, Italy), is performed during the third trimester check-up.

    Thanks to an innovative parameter called Fragility Score (FS), intrinsically correlated with bone quality and independent of BMD, REMS allows assessment of bone fragility and its resulting fracture risk, representing a useful diagnostic tool also in predicting the risk of fragility fractures.

  • questionnairesOther

    Specific questionnaires developed by the Fragility Fracture Observatory (OFF) will be administered. Their purpose is to assess all risk factors that could lead to fractures during pregnancy, as well as to evaluate both dietary habits and adherence to the Mediterranean diet

Study groups in NCT07508553
Study groupRoleWhat they receive
singleton pregnancyExperimentalWomen in physiological pregnancy between the 35th and 41st week, with a single pregnancy
Receives: Device: bone densitometric examination using REMS technology; Other: questionnaires
Twin pregnancyExperimentalWomen in physiological pregnancy between the 35th and 41st week, with a single pregnancy
Receives: Device: bone densitometric examination using REMS technology; Other: questionnaires

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. BMD differences between singleton and twin pregnancies

    To identify, in the third trimester of pregnancy (between the 35th and 41st gestational week), any differences in bone mineral density (BMD) between women with a singleton pregnancy and women with dichorionic and monochorionic twin pregnancies.

    Measured: From enrollment through delivery, an average of six weeks

Secondary outcomes (2)
  1. BMD values and maternal clinical parameter

    Evaluation of the correlation between bone mineral density (BMD), measured by dual-energy X-ray absorptiometry (DEXA) and expressed in g/cm², and the following maternal clinical parameters:

    body mass index (BMI, kg/m²) maternal age (years) weight gain during pregnancy (kg)

    The correlation will be analyzed using a correlation coefficient (Pearson or Spearman, depending on the data distribution).

    Measured: From enrollment through delivery, an average of six weeks

  2. Correlation between bone mineral density (DEXA, g/cm²) and validated questionnaire scores (calcium intake, PREDIMED, AFEF)

    Evaluation of the correlation between bone mineral density (BMD) values, measured by dual-energy X-ray absorptiometry (DEXA) and expressed in g/cm², and:

    • daily dietary calcium intake, assessed using a dedicated questionnaire and expressed in mg/day
    • adherence to the Mediterranean diet, assessed using the PREDIMED questionnaire and expressed as a total score
    • individual risk, assessed using the AFEF questionnaire and expressed as a total score

    The correlation will be analyzed using a correlation coefficient (Pearson or Spearman, depending on the data distribution)

    Measured: From enrollment through delivery, an average of six weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted2 Apr 2026
  2. Study start23 Dec 2025
  3. Primary completion23 Dec 2026 (estimated)
  4. Study completion23 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07508553
Sponsor's protocol ID
8084
Acronym
TWINBONE
Status last verified
Dec 2025
First submitted
23 Dec 2025
Last updated
2 Apr 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing bone densitometric examination using REMS technology and questionnaires in people with Osteoporosis and Pregnancy, run by Fondazione Policlinico Universitario Agostino Gemelli IRCCS at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Tullio Ghi (0630155989, tullio.ghi@policlinicogemelli.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

BMD differences between singleton and twin pregnancies (time frame: From enrollment through delivery, an average of six weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Apr 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in